First real-world clinical experience with [177Lu]Lu-PSMA-I&T in patients with metastatic castration-resistant prostate cancer beyond VISION and TheraP criteria
European Journal of Nuclear Medicine and Molecular Imaging · 2025-05 · 52 (6) · 2034-2040
DOI: 10.1007/s00259-025-07082-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 18.01.2025. Verfasst von Sui Wai Ling und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology & Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Lutetium, Heterocyclic Compounds, 1-Ring, Dipeptides. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
To report real-world clinical experience with [ 177 Lu]Lu-PSMA-I&T targeted radionuclide therapy (TRT) in patients with metastatic castration-resistant prostate cancer (mCRPC) in a single tertiary referral university hospital.
Methods
Patients with mCRPC who were treated with [ 177 Lu]Lu-PSMA-I&T TRT as standard of care between February 2022 and August 2023 were included in this retrospective study. Patients were treated with a maximum of six cycles with a fixed activity of 7.4 GBq/100µg [ 177 Lu]Lu-PSMA-I&T per cycle.
Results
50 patients with mCRPC were included, of them 84% had prior therapy with two lines of taxane-based chemotherapy treated and at least one line of androgen receptor signaling inhibitor. A total of 126 cycles with a median of 2 cycles (IQR 1–6) [ 177 Lu]Lu-PSMA-I&T were administered per patient. PSA declines of ≥ 50% and ≥ 70% were achieved in 16% and 10% of the patients, respectively. Radiological response was achieved in 11% of the patients. In total, 68 treatment-related Adverse Events (TRAEs) were observed, mainly grade 1–2 in 88% of cases. Grade 3/4 TRAEs were observed in 12% of cases. No grade 3 or higher xerostomia was reported. Median progression-free survival was 7.7 months (95% CI 4.0-11.3) and median overall survival was 8.1 months (95% CI 5.0-11.3).
Conclusion
In heavily pretreated patients with mCRPC, treatment of [ 177 Lu]Lu-PSMA-I&T TRT is well tolerated and safe, but real-world efficacy of [ 177 Lu]Lu-PSMA appears lower compared to data from recent phase-3 clinical trials using a different radioligand [ 177 Lu]Lu-PSMA-617. Further studies may show whether patients with mCRPC benefit more from [ 177 Lu]Lu-PSMA when initiated at an earlier stage of treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology & Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands.
- Department of Hospital Pharmacy, Erasmus MC, Rotterdam, The Netherlands.
- Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
- Department of Internal Medicine, Section of Endocrinology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
- Department of Radiology & Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands. t.brabander@erasmusmc.nl.
ORCID-Profile: Tessa Brabander
Zitieren
APA
Ling, S. W., de Lussanet de la Sablonière, Q., Ananta, M., de Blois, E., Koolen, S. L. W., Drexhage, R. C., Hofland, J., Robbrecht, D. G. J., van der Veldt, A. A. M., Verburg, F. A., & Brabander, T. (2025). First real-world clinical experience with [177Lu]Lu-PSMA-I&T in patients with metastatic castration-resistant prostate cancer beyond VISION and TheraP criteria. European Journal of Nuclear Medicine and Molecular Imaging, 52(6), 2034-2040. https://doi.org/10.1007/s00259-025-07082-9
Vancouver
Ling SW, de Lussanet de la Sablonière Q, Ananta M, de Blois E, Koolen SLW, Drexhage RC, et al. First real-world clinical experience with [177Lu]Lu-PSMA-I&T in patients with metastatic castration-resistant prostate cancer beyond VISION and TheraP criteria. European Journal of Nuclear Medicine and Molecular Imaging. 2025;52(6):2034-2040. doi:10.1007/s00259-025-07082-9
BibTeX
@article{Ling2025,
author = {Ling, Sui Wai and de Lussanet de la Sablonière, Quido and Ananta, Michael and de Blois, Erik and Koolen, Stijn L W and Drexhage, Roosmarijn C and Hofland, Johannes and Robbrecht, Debbie G J and van der Veldt, Astrid A M and Verburg, Frederik A and Brabander, Tessa},
title = {First real-world clinical experience with [177Lu]Lu-PSMA-I&T in patients with metastatic castration-resistant prostate cancer beyond VISION and TheraP criteria},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2025},
volume = {52},
number = {6},
pages = {2034--2040},
doi = {10.1007/s00259-025-07082-9}
}
EUVIMED